The SNTA1 antibody targets alpha-1-syntrophin (SNTA1), a scaffolding protein belonging to the syntrophin family, which plays a role in organizing membrane-associated protein complexes. SNTA1 contains multiple protein interaction domains, including a PDZ domain, and interacts with signaling molecules, ion channels, and cytoskeletal components. It is notably involved in the dystrophin-glycoprotein complex (DGC) in muscle and neuronal tissues, contributing to membrane stability, mechanical stress resistance, and signal transduction. SNTA1 also associates with neuronal nitric oxide synthase (nNOS), linking mechanical stress to nitric oxide signaling in muscle.
Antibodies against SNTA1 are widely used in research to study its expression, localization, and interactions in tissues, particularly in skeletal muscle, heart, and brain. They are applied in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to explore SNTA1's role in diseases such as muscular dystrophies, cardiomyopathies, and Brugada syndrome, where SNTA1 mutations or dysregulation have been implicated.
These antibodies are typically raised in hosts like rabbits or mice and validated for specificity using knockout controls. Reliable SNTA1 antibodies are crucial for understanding its physiological functions and pathological mechanisms, aiding in the development of targeted therapeutic strategies.